Pharma Deals Review, Vol 2009, No 10 (2009)

Font Size:  Small  Medium  Large

AstraZeneca Inks Deal with Nektar

Taskin Ahmed

Abstract


AstraZeneca has signed a licensing deal with Nektar Therapeutics to develop and market the latter’s two drugs, NKTR-118 and NKTR-119, for the treatment of constipation, a common side effect of opioid painkillers.



Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.